| First Author | Wang Y | Year | 2022 |
| Journal | Cell Rep | Volume | 40 |
| Issue | 8 | Pages | 111259 |
| PubMed ID | 36001955 | Mgi Jnum | J:344141 |
| Mgi Id | MGI:7334657 | Doi | 10.1016/j.celrep.2022.111259 |
| Citation | Wang Y, et al. (2022) Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia. Cell Rep 40(8):111259 |
| abstractText | Excessive hepatic glucose production contributes to the development of hyperglycemia and is a key feature of type 2 diabetes. Here, we report that activation of hepatocyte Rap1a suppresses gluconeogenic gene expression and glucose production, whereas Rap1a silencing stimulates them. Rap1a activation is suppressed in obese mouse liver, and restoring its activity improves glucose intolerance. As Rap1a's membrane localization and activation depends on its geranylgeranylation, which is inhibited by statins, we show that statin-treated hepatocytes and the human liver have lower active-Rap1a levels. Similar to Rap1a inhibition, statins stimulate hepatic gluconeogenesis and increase fasting blood glucose in obese mice. Geranylgeraniol treatment, which acts as the precursor for geranylgeranyl isoprenoids, restores Rap1a activity and improves statin-mediated glucose intolerance. Mechanistically, Rap1a activation induces actin polymerization, which suppresses gluconeogenesis by Akt-mediated FoxO1 inhibition. Thus, Rap1a regulates hepatic glucose homeostasis, and blocking its activity, via lowering geranylgeranyl isoprenoids, contributes to statin-induced glucose intolerance. |
